
11 Jun 2019
Melvyn’s story
In 2012 Melvyn, a bone marrow transplant patient, suffering from an aggressive form of graft-versus-host-disease was given pioneering, life-saving treatment, Mesenchymal Stem Cell Therapy, at The Catherine Lewis Centre.
“I was first diagnosed with leukaemia in July 1998 after complaining of fatigue to my local GP,” says Melvyn.
“I didn’t know what the disease was at the time but my wife Pauline took the news very badly as she understood what the outcome could be.
“I wanted to see my children graduate – my daughter was 13 and my son 15 – so I was determined to fight it and stay positive. It was a huge shock for my family.”
Melvyn successfully underwent a stem cell transplant just 10 weeks later, and although he responded well initially he started to experience a serious complication called graft-versus-host-disease (GvHD), where the newly transplanted cells attack the recipient’s body.
“I remember reaching out to turn the bedside lamp off and noticing for the first time hard lumps on my arms. By the time I went to clinic, it had spread all over my body from my neck to my ankles and my skin had become so thick that I found it hard to move.
“I saw the rheumatologist and started a new steroid drug regime, it worked well for around two years, but the risk of infection and relapse were so high that I stopped taking them.
“After a couple of years GvHD deteriorated; but thankfully, because of research funded by Leukaemia UK, I was given the opportunity to trial a new treatment called Mesenchymal Stem Cell Therapy, which has significantly improved my life.”
Professor Francesco Dazzi
“Leukaemia UK has enabled us to initiate this treatment and gather preliminary evidence with some extraordinary results. In Melvyn’s case, we isolated cells taken from his daughter, prepared them here at The Catherine Lewis Centre and, when they were ready, we infused them.
“We have seen a 50% improvement in Melvyn’s condition and I am thrilled that we have been able to improve both his outlook and quality of life.”
Related posts
22 May 2023
Can the unique differences between stem cells tell us how well CML treatment will work?
What if we could predict how chronic myeloid leukaemia (CML) patients will respond to treatment? Could the unique signatures of CML stem cells hold the key to personalising treatment for…
13 November 2023
This year’s Olive Boles Innovation Award winner announced
Dr Kevin Rattigan, University of Glasgow, has been selected as this year’s Olive Boles Innovation Award winner – an accolade given to one Leukaemia UK John Goldman Fellow each year….
16 November 2022
Cost of Living with Leukaemia Fund launches
Leukaemia Care and Leukaemia UK have launched a new financial support service, the Cost of Living with Leukaemia Fund, in response to the cost of living crisis in the UK….
24 August 2022
Non-existent awareness of leukaemia symptoms “extremely worrying” – say leading UK leukaemia charities, as they launch memorable new campaign to get people “parroting on” about the symptoms
People over 55 also underestimate their risk, thinking that leukaemia is a childhood disease. Only 11% of over 55s thought that they had the greatest risk of leukaemia[1], whereas in…